

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.\***

**樂普心泰醫療科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2291)**

## **INSIDE INFORMATION AND RESUMPTION OF TRADING**

This announcement is made by LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.\* (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement of the Company dated April 22, 2025.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company noted the recent fluctuation in the price and trading volume of the shares of the Company on the Stock Exchange and the investor relation activity record sheet published by Lepu Medical Technology (Beijing) Co., Ltd.# (樂普(北京)醫療器械股份有限公司), whose shares are listed on the ChiNext Board of the Shenzhen Stock Exchange, stock code: 300003, one of the Company’s controlling shareholders, on April 21, 2025, which referred to the expected increase target of the sales of the occluder product of approximately 30% and the expected sales target of the transcatheter aortic valve replacement product of approximately RMB200 million, of the Company, respectively, the realization of which is uncertain and subject to market condition.

Save for the abovementioned information, based on the understanding of the Company, the recent price and trading volume movements of the shares of the Company also represent the investors’ recognition in the continuous growth in the results and the performance of the Company and reflect the restoration of the value of the Company, and the Board confirms that it is not aware of any other reasons for these price and trading volume movements or of any inside information that needs to be disclosed under Part XIVA of the SFO.

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been halted with effect from 10:57 a.m. on Tuesday, April 22, 2025, pending release of this announcement. An application has been made by the Company to the Stock Exchange for the resumption of trading in the shares of the Company with effect from 9:00 a.m. on Wednesday, April 23, 2025.

By order of the Board  
**LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.\***  
樂普心泰醫療科技(上海)股份有限公司  
**Ms. Chen Juan**  
*Chairman of the Board and Executive Director*

Shanghai, the People's Republic of China  
April 22, 2025

*As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.*

# *For identification purposes only*

\* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*